Research Disclosures & Disclaimers

This website contains disclosures and disclaimers related to
published UBS Global Research products, including those related to
regulation, potential conflicts of interest as well as those provided
by third-party data providers describing limitations on use of their
products.

Novartis (NOVN.S)

UBS Rating and Price Target History Chart

Line chart explaining Price target vs Stock Price is described in below table

EQ Rating & Price Target Table

Date	Stock Price (CHF)	Price Target (CHF)	Rating
2021-08-20	79.91	89.76	Buy
2021-08-24	79.03	88.825	Buy
2021-10-08	71.62	86.02	Buy
2021-11-05	71.14	74.80	Neutral
2022-01-07	76.42	76.67	Neutral
2022-02-08	75.01	78.54	Neutral
2022-04-08	81.09	79.475	Neutral
2022-04-27	81.17	82.28	Neutral
2022-06-30	75.59	80.41	Neutral
2022-09-26	69.17	74.80	Neutral
2022-12-02	78.67	76.67	Neutral
2022-12-14	80.53	78.54	Neutral
2023-01-09	79.76	77.605	Neutral
2023-02-14	75.19	79.475	Neutral
2023-02-22	75.85	80.41	Neutral
2023-05-18	85.14	92.565	Neutral
2023-07-19	83.17	88.825	Neutral
2023-10-04	87.60	90.00	Neutral
2024-01-15	92.00	104.00	Buy
2024-04-24	89.12	108.00	Buy
2024-07-19	94.20	111.00	Buy

Disclosures

UBS has acted as manager/co-manager in the underwriting or placement of securities of this company/entity or one of its affiliates within the past 12 months.
Within the past 12 months, UBS has received compensation for investment banking services from this company/entity or one of its affiliates.
UBS expects to receive or intend to seek compensation for investment banking services from this company/entity within the next three months.
Within the past 12 months, UBS has received compensation for products and services other than investment banking services from this company/entity.
UBS beneficially owned 1% or more of a class of this company`s common equity securities as of last month`s end (or the prior month`s end if this report is dated less than 10 days after the most recent month`s end).
UBS Securities LLC makes a market in the securities and/or ADRs of this company.
UBS holds a long or short position of 0.5% or more of the listed shares of this company.
UBS Fund Management (Switzerland) AG beneficially owns more than 5% of the total issued share capital of this company.

Note : Historical Price Targets have been adjusted to account for any stock splits, rights issues and/or dividends which may have occurred for this security. Not Priced: Stock was not priced on the given date. No Rating: Issuer was not rated by UBS on the given day. No Price Target: For this issuer no Price Target was set by UBS on the given day.